Aligos Therapeutics, Inc. (ALGS) Misses Q3 EPS by 290c
Tweet
Share
E-mailGet Alerts ALGS Hot Sheet
Join SI Premium – FREE
Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q3 EPS of ($3.07), $2.90 worse than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- StablecoinX reports Q2 2026 results with $34.2M net loss
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
